3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
58
Filgrastim
37
Radiotherapy
31
Busulfan
28
fludarabine phosphate
26
Antilymphocyte Serum
25
Cyclosporine
24
Peripheral Blood Stem Cell Transplantation
23
Etoposide
22
Methotrexate
20
Melphalan
18
Mycophenolic Acid
17
Cord Blood Stem Cell Transplantation
17
Methylprednisolone
16
Vincristine
13
Cytarabine
13
Tacrolimus
12
Rituximab
11
Whole-Body Irradiation
9
Thiotepa
9
Prednisone
9
Doxorubicin
8
Leucovorin
7
sargramostim
6
aldesleukin
6
Granulocyte Colony-Stimulating Factor
6
Psychiatric Rehabilitation
5
Daunorubicin
5
pembrolizumab
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
CLR1404
×
Sarcoma
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled